API

A steroid is a type of organic compound that contains...

read more...

Pharma Intermediate

Pharmaceuticals refer to the drugs and medicines...

read more...

Speciality Chemicals

Specialty chemicals are those chemicals which is produced...

read more...

Products Under Devp.

New Products Under Development In response...

read more...

AUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER 2008
(Rs. In Lacs)

 

Particulars Quarter ended Quarter ended Half Year Ended Half Year Ended Year ended
31st Dec 2008 31st Dec 2007 31st Dec 2008 31st Dec 2007 31st Mar 2008
1.
(a)
(Net) Sales / Income from operations
9,161 6,659 27,465 20,478 31,073
(b) Other Operating Income
2. Expenditure
(a)
(Increase) / Decrease in stock in trade & WIP.
670 (1,000) (517) (1,929) (924)
(b) Consumption of raw materials. 5,286 4,989 16,921 13,893 18,259
(c) Purchase of Traded Goods 612 357 2,132 1,570 3,892
(d) Employees cost 255 236 778 704 980
(e) Depreciation 266 235 785 711 963
(f) Other expenditure 1,336 1,178 4,113 3,524 5,119
(g) Total Expenditure 8,425 5,995 24,212 18,492 28,289
3.
Profit from Operations before Other Income, Interest & Exceptional Item
736 665 3,253 1,986 2,783
4. Other Income 10 22 16 88 184
5.
Profit before Interest & Exceptional Items
746 687 3,269 2,074 2,967
6. Interest 600 232 1,764 597 1,184
7.
Profit after Interest but before Exceptional Items
146 455 1,505 1,477 1,783
8. Exceptional Items - - - - -
9.
Profit from Ordinary Activities before Tax
146 455 1,505 1,477 1,184
10. Tax Expenses (Includes) 91 127 457 352 476
(a) Provision for Taxation 35 55 268 175 230
(b) Provision for FBT 4 7 11 12 16
(c) Provision for Deffered Taxation 53 65 178 165 230
11.
Net profit from ordinary Activities after Tax
55 328 1,049 1,126 1,307
12.
Extraordinay Item (net of tax expenses )
- - - - -
13. Net Profit for the period 55 328 1,049 1,126 1,307
14.
Paid-up Equity Share Capital of Rs.10/- each.
1,171 1,171 1,171 1,171 1,171
15.
Reserves & Surplus (excluding revaluation reserves)
- - - - -
16. Basic & Diluted E P S(in Rs.) 0.47 2.80 8.96 9.61 11.17
17. Public shareholding
-Number of Shares 5627201 6113030 5627201 6113030 6045866
-Percentage of Total Shareholding 48.06 52.21 48.06 52.21 51.64

Notes :

1. There were no pending complaints at the beginning of the Quarter. During the quarter three complaints were received and redressed. There were no complaints pending at the end of the quarter.

2. Company is operating as a Single Segment Company, engaged in pharmaceuticals business hence, the disclosure requirement as per AS - 17 'Segment Reporting' is not attracted.

3. The figures of the previous periods have been regrouped and rearranged wherever necessary.

4. Number of Investors complaints (i) pending at the beginning of quarter 1 (ii) received during the quarter : 10 (Iii) redressed : 10 (iv) pending at the end of the quarter : 1.

For and on behalf of the Board

FOR AARTI DRUGS LIMITED

Sd/-

Place : Mumbai Harshit M Savla

Date : 30th Oct, 2009 (Jt. Managing Director)

 

Resource Download

Annual Report
Click here to download
annual report
Investor Presentation
Click here to download
Presentation

Copyright © 2010 Aarti Drugs Ltd. All Rights Reserved
Website Developed by : Sri Hema Infotech